文献速递冠心病

ISCHEMIA试验中心肌梗死不同定义对发生率、预后及治疗比较的影响

Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons.
PubMed 文献 · Circulation · 2020-12-03

ISCHEMIA试验在稳定性缺血性心脏病和中重度心肌缺血患者中比较初始侵入性与保守策略,预设使用两种MI定义分析复合终点。结果显示保守策略下1型MI更常见且与后续心血管死亡相关,侵入性策略下手术相关MI更多,使用次要定义时更明显。

要点

  • 保守策略下1型MI发生率更高,且1型MI后心血管死亡风险增加。
  • 侵入性策略下手术相关MI更多,使用次要定义时比例更高。
  • 两种MI定义下治疗比较方向一致,但事件率不同。

核心结论

  • 在ISCHEMIA试验5年随访中,使用主要和次要定义,初始保守策略下1型MI事件更频繁,并与后续心血管死亡相关。
  • 侵入性策略下手术相关MI发生率更高,且使用次要MI定义时更高。

研究设计与样本

  • ISCHEMIA试验预设使用两种MI定义分析主要和主要次要复合终点。
  • 手术相关MI的主要定义以肌酸激酶-MB为首选生物标志物,次要定义使用心肌肌钙蛋白。
  • 经皮冠状动脉介入治疗的手术相关阈值>5倍参考上限,冠状动脉旁路移植术>10倍。

主要发现

  • 手术相关MI占所有MI事件的20.1%(主要定义)和40.6%(次要定义)。
  • 接受血运重建的患者4年MI率:侵入性vs保守策略,主要定义2.7% vs 1.1%(校正HR 2.98,95%CI 1.87-4.73),次要定义8.2% vs 2.0%(校正HR 5.04,95%CI 3.64-6.97)。
  • 1型MI发生率:侵入性vs保守策略,主要定义3.40% vs 6.89%(校正HR 0.53,95%CI 0.41-0.69,P<0.0001),次要定义3.48% vs 6.89%(校正HR 0.53,95%CI 0.41-0.69,P<0.0001)。
  • 1型MI后心血管死亡风险高于无MI:主要定义校正HR 3.38(95%CI 2.03-5.61,P<0.001),次要定义校正HR 3.52(95%CI 2.11-5.88,P<0.001)。

关键数值与推荐

  • 手术相关MI主要定义:肌酸激酶-MB>5倍参考上限(PCI)或>10倍(CABG),并包括生物标志物升高伴新发ST段压低≥1 mm或新发冠状动脉夹层>NHLBI 3级。
  • 手术相关MI次要定义:心肌肌钙蛋白>5倍参考上限(PCI)或>10倍(CABG),并包括生物标志物升高伴新发ST段压低≥0.5 mm或新发冠状动脉夹层>NHLBI 3级。

临床怎么用

  • 解读ISCHEMIA结果时需注意MI定义对事件率的影响,尤其是手术相关MI。
  • 侵入性策略减少1型MI但增加手术相关MI,临床决策需权衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the ISCHEMIA trial (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches), an initial invasive strategy did not significantly reduce rates of cardiovascular events or all-cause mortality in comparison with a conservative strategy in patients with stable ischemic heart disease and moderate/severe myocardial ischemia. The most frequent component of composite cardiovascular end points was myocardial infarction (MI). METHODS: ISCHEMIA prespecified that the primary and major secondary composite end points of the trial be analyzed using 2 MI definitions. For procedural MI, the primary MI definition used creatine kinase-MB as the preferred biomarker, whereas the secondary definition used cardiac troponin. Procedural thresholds were >5 times the upper reference level for percutaneous coronary intervention and >10 times for coronary artery bypass grafting. Procedural MI definitions included (1) a category of elevated biomarker only events with much higher biomarker thresholds, (2) new ST-segment depression of ≥1 mm for the primary and ≥0.5 mm for the secondary definition, and (3) new coronary dissections >National Heart, Lung, and Blood Institute grade 3. We compared MI type, frequency, and prognosis by treatment assignment using both MI definitions. RESULTS: Procedural MIs accounted for 20.1% of all MI events with the primary definition and 40.6% of all MI events with the secondary definition. Four-year MI rates in patients undergoing revascularization were more frequent with the invasive versus conservative strategy using the primary (2.7% versus 1.1%; adjusted hazard ratio [HR], 2.98 [95% CI, 1.87-4.73]) and secondary (8.2% versus 2.0%; adjusted HR, 5.04 [95% CI, 3.64-6.97]) MI definitions. Type 1 MIs were less frequent with the invasive versus conservative strategy using the primary (3.40% versus 6.89%; adjusted HR, 0.53 [95% CI, 0.41-0.69]; P<0.0001) and secondary (3.48% versus 6.89%; adjusted HR, 0.53 [95% CI, 0.41-0.69]; P<0.0001) definitions. The risk of subsequent cardiovascular death was higher after a type 1 MI than after no MI using the primary (adjusted HR, 3.38 [95% CI, 2.03-5.61]; P<0.001) or secondary MI definition (adjusted HR, 3.52 [2.11-5.88]; P<0.001). CONCLUSIONS: In ISCHEMIA, type 1 MI events using the primary and secondary definitions during 5-year follow-up were more frequent with an initial conservative strategy and associated with subsequent cardiovascular death. Procedural MI rates were greater in the invasive strategy and with the use of the secondary MI definition. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01471522.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Chaitman BR, Alexander KP, Cyr DD, et al. Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. Circulation. 2020. PMID: 33267610. doi:10.1161/CIRCULATIONAHA.120.047987

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。